Did Kepivance® help reduce downstream clinical consequences of severe oral mucositis?
Kepivance® helped patients continue to perform basic daily activities such as eating, drinking, swallowing, and talking. Kepivance® also reduced opioid use and total parenteral nutrition (TPN). Patients receiving Kepivance® required a median of 4 fewer days of opioid analgesics compared to patients receiving placebo. The cumulative dose required was lower in patients receiving Kepivance® compared to patients receiving placebo (212 mg of morphine equivalents vs 535 mg of morphine equivalents; P < 0.001). Kepivance® also reduced the incidence of TPN by 44% compared to patients receiving placebo (31% vs 55% for placebo; P < 0.001).
